Statins and non‐alcoholic fatty liver disease
In April 9 issue, van den Berg EH et al.1 report interesting results on the indication for lipid-lowering treatment in a large cohort with suspected NAFLD within the population-based Lifelines Cohort Study. FLI≥60 was used as a proxy of NAFLD and the NAFLD fibrosis score (NFS) to identify NAFLD patients with suspected advanced fibrosis. CVD risk was established by the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias2 .
This article is protected by copyright. All rights reserved.